3741 completed, 1159 recruiting, 1125 unknown, 992 terminated. 3697 Phase 2, 2854 Phase 1, 803 Not applicable, 697 Phase 3, 166 Early Phase 1.
Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLASH Pilot Phase 1 Safety Study IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma | Not applicable | Not yet recruiting | Lesley A. Jarvis | 10 | 2029-10-31 | 2026-05-27 |
| Family-Focused Study to Support Medication for Opioid Use Disorder FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate | Not applicable | Not yet recruiting | University of Wisconsin, Madison | 338 | 2027-08-31 | 2026-07-07 |
| Astragalus for Symptomatic Alleviation in High-grade Lymphoma Astragalus, Placebo - High-grade Lymphoma | Phase 3 | Not yet recruiting | Bnai Zion Medical Center | 60 | 2027-08-01 | 2026-09-30 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-11-02 |
| Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome | Phase 1 | Not yet recruiting | City of Hope Medical Center | 14 | 2027-05-16 | 2026-11-09 |
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma golcadomide, Obinutuzumab, Polatuzumab - Multi Center, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-04-29 | 2026-11-05 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-11-13 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Molecular and Cellular Characterization of MALT Lymphoma MALT Lymphoma | Not yet recruiting | International Extranodal Lymphoma Study Group (IELSG) | 400 | 2027-04-01 | 2026-11-12 | |
| Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL) Asciminib, Inotuzumab ozogamicin - B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Recruiting | Sunil G. Iyer | 45 | 2027-03-31 | 2026-11-13 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | University of Washington | 27 | 2027-03-01 | 2026-11-02 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-22 |
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-11-02 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL | Phase 1 | Not yet recruiting | Medical University of South Carolina | 18 | 2027-02-01 | 2026-11-13 |
Showing 20 of 8390. Sign in to see all of them.
Lymphoma, Non-Hodgkin (2287) · Lymphoma, Follicular (1875) · Lymphoma, Large B-Cell, Diffuse (1831) · Hodgkin Disease (1301) · Lymphoma, Mantle-Cell (1211) · Leukemia, Lymphocytic, Chronic, B-Cell (1126) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1025) · Burkitt Lymphoma (977) · Leukemia (883) · Lymphoma, B-Cell, Marginal Zone (865) · Multiple Myeloma (817) · Lymphoma, B-Cell (780) · Recurrence (733) · Leukemia, Myeloid, Acute (603)
Neoplasms by Histologic Type (8362) · Hemic and Lymphatic Diseases (8308) · Immune System Diseases (8251) · Immunoproliferative Disorders (8249) · Lymphatic Diseases (8244) · Lymphoproliferative Disorders (8178) · Neoplasms (7914) · Lymphoma, Non-Hodgkin (4123) · Hematologic Diseases (2636) · Lymphoma, B-Cell (2337) · Pathological Conditions, Signs and Symptoms (2183) · Pathologic Processes (2052) · Disease Attributes (1859) · Leukemia, Lymphoid (1728)
Rituximab (1192) · Cyclophosphamide (1029) · Vincristine (519) · Doxorubicin (507) · Prednisone (454) · Etoposide (447) · fludarabine (329) · Cytarabine (308) · Lenalidomide (291) · fludarabine phosphate (284) · Filgrastim (282) · Methotrexate (263) · Dexamethasone (251) · Radiotherapy (229) · Bendamustine Hydrochloride (219)
National Cancer Institute (NCI) (411) · M.D. Anderson Cancer Center (268) · Memorial Sloan Kettering Cancer Center (179) · Fred Hutchinson Cancer Center (114) · City of Hope Medical Center (106) · Ruijin Hospital (97) · Hoffmann-La Roche (89) · Novartis Pharmaceuticals (76) · Fondazione Italiana Linfomi - ETS (72) · Celgene (66) · Mayo Clinic (64) · St. Jude Children's Research Hospital (61) · Sun Yat-sen University (59) · Children's Oncology Group (57) · Dana-Farber Cancer Institute (55)
United States (4482) · China (1374) · France (778) · Italy (639) · United Kingdom (551) · Germany (512) · Canada (511) · Spain (509) · Australia (410) · South Korea (365) · Belgium (298) · Poland (273) · Japan (230) · Netherlands (222) · Israel (196)
Ajay Gopal (16)
PMID 34515338, PMID 41671463, PMID 40135712, PMID 32632956, PMID 32499241, PMID 35622074, PMID 31401903, PMID 40550489, PMID 39319495, PMID 26373676, PMID 37505794, PMID 27282998, PMID 40802906, PMID 23834234, PMID 30125215, PMID 31050355, PMID 32816215, PMID 34398557, PMID 35787017, PMID 19238148, PMID 32770353, PMID 33288485, PMID 33883258, PMID 34780125, PMID 34806163, PMID 39563886, PMID 39813680, PMID 17242396, PMID 20660832, PMID 20679620, PMID 21403127, PMID 22430088, PMID 22510871, PMID 23065508, PMID 23524640, PMID 23753028, PMID 25113753, PMID 25381051, PMID 27209293, PMID 28054442, PMID 30010775, PMID 30518502, PMID 30620669, PMID 30770362, PMID 31196847, PMID 32589970, PMID 32596842, PMID 32705923, PMID 32823563, PMID 33795208
2023 (80), P30CA033572 (77), P30CA015704 (58), 2015 (49), 2017 (45), 2016 (43), U10CA180820 (43), U10CA032102 (41), 2018 (38), 2014 (32), P30CA043703 (32), P30CA015083 (31), U10CA031946 (30), U10CA180886 (29), P30CA016672 (28)